exhibit_99-1.htm

Exhibit 99.1

KAMADA
INVESTOR PRESENTATION

September 2014

NASDAQ: KMDA

Forward Looking Statement

This presentation is not intended to provide investment or medical advice. It should be noted that some products under development described herein have not been found safe or
effective by any regulatory agency and are not approved for any use outside of clinical trials.

This presentation contains forward-looking statements, which express the current beliefs and expectations of Kamada’s management. Such statements involve a number of known
and unknown risks and uncertainties that could cause Kamada's future results, performance or achievements to differ significantly from the results, performance or achievements
expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to Kamada's ability to
successfully develop and commercialize its pharmaceutical products, the progress and results of any clinical trials, the introduction of competing products, the impact of any
changes in regulation and legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Agency and
other regulatory authority approvals, the regulatory environment and changes in the health policies and structures of various countries, environmental risks, changes in the
worldwide pharmaceutical industry and other factors that are discussed in Kamada's prospectus related to this offering.

This presentation includes certain non-GAAP financial information, which is not intended to be considered in isolation or as a substitute for, or superior to, the financial information
prepared and presented in accordance with GAAP. The non-GAAP financial measures may be calculated differently from, and therefore may not be comparable to, similarly titled
measures used by other companies. A reconciliation of these non-GAAP financial measures to the comparable GAAP measures is included in an appendix to this presentation.
Management uses these non-GAAP financial measures for financial and operational decision-making and as a means to evaluate period-to-period comparisons. Management
believes that these non-GAAP financial measures provide meaningful supplemental information regarding Kamada’s performance and liquidity.

The issuer has filed a registration statement (including a prospectus) with the US Securities and Exchange Commission (the “SEC”) for the offering to which this communication
relates. Before you invest, you should read the prospectus in that registration statement and other documents the issuer has filed with the SEC for more complete information
about the issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, a copy of the prospectus may be
obtained from the offices of Morgan Stanley & Co. LLC, Attention: Prospectus Department 180 Varick Street, 2nd Floor, New York, New York 10014; telephone 866-718-1649; email:
prospectus@morganstanley.com or from Jefferies LLC at 520 Madison Avenue, 12th Floor, New York, NY, 10022, Attention: Equity Syndicate Prospectus Department; telephone
(877) 547-6340; email: Prospectus_Department@Jefferies.com.

Investor Presentation | Sep. 2014

Kamada Overview

• AAT deficiency (AATD) is a genetic emphysema, caused by lack
of protein

• Existing Therapy is replacement of the protein

• Completed Phase II/III trials in EU- pursuing conditional
approval

• Ongoing Phase II in the US- pathway to be discusses with FDA

• Upside in Type 1 Diabetes

Notes

1. As of June 30, 2014

2. Market data as of Aug 31 2014

3. See Appendix for a reconciliation of Adjusted EBITDA to IFRS Net Profit (Loss)

Key Statistics

• Founded in 1990 and based in Weizmann Science Park, Israel

• Employees: ~300 (1)

• Listed on NASDAQ since 2013 & TASE since 2005 (KMDA)

• Current market capitalization: ~$250MM (2)

• Cash, cash equivalents and ST investments: $68MM(1)

• Total Debt: $17.6MM (1)

Historical Adjusted EBITDA (3)

$MM

Historical Revenue

Investor Presentation | Sep. 2014

Diverse Portfolio of Predominantly Plasma-Derived Protein Therapeutics

Global Presence with Exposure to Emerging Markets

Growing Proprietary Products Segment Through Glassia® and Inhaled AAT Product

Respiratory

Glassia®

Immunoglobulin

KamRAB™

KamRho (D) IM

KamRho (D) IV

Other Products

Heparin Lock Flush

Kamacaine 0.5%

Human Transferrin

Respiratory

Bramitob

Foster

Immunoglobulins

IVIG 5%

Varitect

Hepatect CP

Megalotect

Zutectra

Critical Care

Heparin sodium injection

Albumin

Other

Factor VIII

Factor IX

Proprietary
Products
Segment

2013 Revenue:
$51MM

Distribution
Segment

2013 Revenue:
$20MM

Alpha-1 Antitrypsin (human)

Anti-rabies immunoglobulin (human)

Rho(D) immunoglobulin (human)

Heparin sodium

Bupivacaine HCl

Transferrin (Diagnostic grade)

Tobramycin

Beclomethasone+Formoterol

Gamma globulins (IgG) (human)

Varicella zoster immunoglobulin (human)

Hepatitis B immunoglobulin (human)

CMV immunoglobulin (human)

Hepatitis B Immunoglobulins S.C

Heparin sodium

Human serum Albumin

Coagulation Factor VIII (human)

Coagulation Factor IX (human)

*Kamada distributes products directly in Israel through its own salesforce

Countries where Kamada currently sells certain of its Proprietary Products through strategic
or distributor partnerships

United States

Mexico

El Salvador

Brazil

Argentina

Slovenia

Croatia

Nigeria

Kenya

India

Thailand

South Korea

Russia

Turkey

Israel*

Chile

Sri Lanka

Countries where Kamada has received regulatory approvals for certain of its Proprietary
Products

Snake Antiserum

Anti-snake venom

Investor Presentation | Sep. 2014

Kamada Investment Highlights

Rapidly Growing, Globally Positioned Biopharmaceutical Company

- Focused on Orphan Diseases and Plasma Derived Protein Therapeutics

Significant Opportunity in Novel Inhaled AAT for Alpha-1 Antitrypsin Deficiency
and in Intravenous AAT for Type-1 Diabetes

Valuable R&D Pipeline Focused on Various Orphan Indications

Integrated, Efficient and Scalable Best-in-class Patented Platform Technology and Know-How

Strong Financial Profile with Increasing Profitability

Validating Strategic Partnerships with Industry Leaders Baxter, Chiesi, Kedrion and Pari Pharma

Flagship Product Glassia® Approved for Alpha-1 Antitrypsin Deficiency

- Has a Unique and Differentiated Product Profile and Represents an Exciting Growth Opportunity

Investor Presentation | Sep. 2014

Glassia® Is A Differentiated Product

P Glassia® is the first and only liquid, ready-to-use, IV
plasma-derived AAT product

P No reconstitution required, reducing risk of
contamination and infection and reducing treatment
time

P Potentially reduced risk for adverse event and/or
allergic reaction due to the absence of preservatives
and stabilizing agent(s)

P Glassia® is sold by Baxter, a leading plasma
therapeutics company in the US

P Significantly faster infusion rate was recently
approved by the US-FDA

Key Product Advantages

AATD (IV) Product Sales and Milestone Revenues

Sold in 7 countries, with majority of sales in the US

Investor Presentation | Sep. 2014

Significant Opportunity to Expand the AATD Market

• Patients suffering from AAT Deficiency (“AATD”) remain
under-identified and under-treated

– Only ~6% of cases treated in the US and ~2% in EU

• Simple blood test for diagnosis expected to impact
demand

• Greater AAT use in Europe and other geographies could
further accelerate market growth

• Chronic therapy creates sustainable product
opportunity

• Average annual cost of treatment estimated at ~$80-
$100K per patient

Sustainable Market with Strong Growth Potential

North America and Europe AATD Patient Counts

Source MRB and Company estimates

Source Alpha 1 Foundation, MRB and Company estimates

Source MRB and Company estimates

(000s)

Investor Presentation | Sep. 2014

Growth of Glassia® Driven by Strategic Partnership

P Sales to Baxter commenced in September 2010

P Agreements: distribution, technology license and fraction IV supply

P Product: AAT IV (Glassia®), including future AAT IV

P Territories: US, Canada, Australia and New Zealand

P Milestone and upfront revenues: $45MM ($34.5MM received)

P Royalties from sales of Glassia® produced by Baxter expected from 2017

P Agreement recently extended:

– Baxter to distribute Glassia® produced by Kamada through 2016

– Minimum revenues of $165MM through 2016 ($94MM already recognized through 12/31/2013)

Strategic Partnership with Baxter

Investor Presentation | Sep. 2014

High Value Pipeline Focused on Orphan Indications

	Product	Indication	Phase I	Phase II	Phase III	Market	Partners
1	Intravenous AAT	AAT Deficiency					US:
2	D1-AAT (IV)	Type 1 Diabetes*					US:
3	G1-AAT (IV)	GVHD					US:
4	Inhaled AAT	AAT Deficiency*					EU:
5	B1-AAT (IH)	Bronchiectasis*
6	C1-AAT (IH)	Cystic Fibrosis (CF)*
7	KamRAB (IM)	Prophylaxis of Rabies					US:

Phase III Completed (LPO)

Ph II/III In Process

FDA Approved (2010)

Completed

Ph I/II In Process

US: IND

Approved

US: Ph II In
Process

EU: Completed

Completed

* Orphan drug designation

Investor Presentation | Sep. 2014

Inhaled AAT Is A Significant Opportunity

ü Chiesi distribution agreement as of August 2012

ü Agreement: Chiesi responsible for S&M, patient ID,
and reimbursement

ü Product: AAT for AATD Inhaled only

ü Territories: EU and Turkey

ü Milestone revenues: $60MM upfront, regulatory and
sales

ü Distributor price

ü Minimum purchases from 2nd yr following receipt of
regulatory and reimbursement approvals, ~$120MM
for first 4 years, subject to actual price after
regulatory approval

Strategic Partnership with Chiesi

P First and only Inhaled AAT product for AATD

– Device and drug combination enable optimal size
particles delivered directly to diseased tissue

P Positive data to date in AATD and strong safety profile

P Potential to expand AATD market, particularly in
Europe

P Potential Inhaled AATD launch in Europe not before
2016 , pursuing conditional approval based on phase 4
commitment.

P US pathway to be discussed with FDA beginning 2015

Inhaled AAT Highlights

Investor Presentation | Sep. 2014

Expected to Launch 2016 in the EU

Indicative Development Timeline:

EMA raparteur
meeting (4Q14) re
Inhaled AAT for
AATD in the EU

Completion of
Phase II Inhaled
AAT for AATD
clinical trial

Inhaled AAT for
AATD MAA filing

Meeting with
FDA re Inhaled
AAT for AATD in
the US

EU launch for
Inhaled AAT for
AATD
(if approved)

2015

2014

2016

2017

Investor Presentation | Sep. 2014

Inhaled AAT for AATD Completed Pivotal Phase II/III Trials
in Europe and Initiated Phase II in the US

Phase II / III EU

Phase II US

Description

• Randomized; Sample size of ~ 36-40 subjects

• Double blind, placebo controlled, randomized

Route &
Dosage Form

• Inhalation of human AAT, 160mg total, twice daily
~10-15 minutes; eFlow® device

• Inhalation of human AAT; two dosage groups (80mg
and 160mg daily); eFlow® device

Clinical
Endpoints

• Exacerbation events (Primary: time to first
moderate/severe, Secondary (among others): rate,
severity of first event; Lung Function)

• Primary: Concentration of AAT in ELF

• Secondary: safety and tolerability, Concentration
AAT in serum, ELF inflammatory analytes

Duration

• 50 wk treatment in DB period; daily treatment

• 50 wk open label extension ; daily treatment

• DB part - Study completed

• 12 weeks double blind +

• 12 weeks open label extension

• Study initiated in 1Q2014

Investor Presentation | Sep. 2014

• Primary and secondary endpoints didn’t demonstrate statistical significant difference

• First AAT deficiency treatment to show impact on lung function

• Concordance of the data in lung function and signals in reduction in exacerbation frequency and
severity in favor of AAT , and in particular, for the frequent exacerbators, suggests possible
therapeutic benefit of AAT

• Study supports understanding the mechanism of action of the disease and the treatment - lung
inflammation

• The company is advancing its discussions with the European Medicines Agency with the intent to
submit for conditional approval on the basis of:

o Orphan drug & Unmet need

o Concordance of data for ITT and frequent exacerbators

o Prior discussions with the regulator

o Precedents of similar cases for drugs of orphan diseases

Inhaled AAT Phase 2-3 trial Results
Summary of the Results

Investor Presentation | Sep. 2014

Inhaled AAT Phase 2-3 trial Results

Parameter	ITT	Frequent exacerbators
Primary endpoint : “Time to the first moderate or severe exacerbation event”	No differences observed	Clinical difference observed AAT vs PL Hazard ratio = 0.877 ( 95% CI 0.563, 1.364) . P Value= NS
Secondary endpoint : “Time to first event-based exacerbation with a severity of mild, moderate or severe	No differences observed	Clinical difference observed AAT vs PL Hazard ratio = 1.064 ( 95% CI 0.717, 1.578) . P Value= NS
Secondary endpoint : “Severity of the first exacerbation event”	Lower number of first severe (Type 1, SB) events vs PL (18.8% and 31.1%, respectively. P Value= NS). Lower number of first moderate (EB*) events vs PL (56.5% and 63.9%, respectively. P Value= NS)	Lower number of first severe (Type 1) events vs PL (19.4% and 35.2%, respectively. P Value= NS). Lower number of first severe /moderate events vs PL (44.8% and 51.9%, respectively. P Value= NS) 15.1% lower number of first moderate (EB) events vs PL . P Value= NS 4.7% lower number of first moderate/ severe (EB) events vs PL. P Value= NS
Secondary endpoint : “Rate of event-based exacerbation episodes”***	No differences observed	Reduction of 10% in AAT group vs PL in mild/ moderate/ severe (EB) events Reduction of 13% in the number of moderate (EB) events Reduction of 12% in the number moderate/ severe (EB) events. P Value, for all measurements= NS

* Symptom based definition

** Event based definition

***The number of mild, moderate or severe event-based exacerbations per patient during the treatment period.

Investor Presentation | Sep. 2014

Inhaled AAT Phase 2-3 trial Results (cont.)

Parameter	ITT	Frequent exacerbators
Lung function: FEV1 % of SVC Change from baseline till end of treatment	+0.34% AAT vs -1.17% PL P Value= 0. 033	+0.2251% AAT vs -1.68% PL P Value= 0. 0208
Lung function: FEV1 % predicted Change from baseline till end of treatment	-0.509 AAT vs -1.37 PL P Value= NS	-0.58 AAT vs. -1.21 PL P Value= NS
Lung function: FEV1 (liters) Change from baseline till end of treatment	-25ml AAT vs -52ml PL P Value= NS	-18ml AAT vs -51ml PL P Value= NS
DLCO [mMol/min/Kpa]	-0.168 % AAT vs -0.28% PL P Value= NS	-0.206% AAT vs -0.336% PL P Value= NS

Dr Jan Stolk , Principal Investigator of the Inhaled AAT phase 2-3 study,
Department of Pulmonology Leiden University Medical Center, Leiden, The Netherlands:

“This study is the first study ever that suggests inhaled AAT’s ability to potentially reduce lung inflammation as expressed by its
preservation of lung function and the trends shown in the reduction in intensity of exacerbation events. I am encouraged by
these results and hope that the regulatory authorities will acknowledge the progress in clinical research demonstrated in this
trial.“

Investor Presentation | Sep. 2014

Inhaled AAT Phase 2-3 trial Results:
Lung Function Graphs

Investor Presentation | Sep. 2014

AAT (IV) is a Promising Potential Treatment
For Newly Diagnosed Type‐1 Diabetes Patients

Investor Presentation | Sep. 2014

Type-1 Diabetes
occurs when the immune system
attacks and destroys beta cells
in the pancreas

Studies have shown that
AAT protects beta cell islets

Preservation of beta cells
correlates with reduced risk
of long term complications

• more than 10 million suffer from T1D
globally

• 100,000 new patients diagnosed annually

• In the US alone: 3 million patients,
with 30,000 new patients diagnosed
annually

• Delays the onset of autoimmune diabetes

• Reduces the incidence of diabetes

• Inhibits insulitis and beta-cell apoptosis

• Decreases beta-cell inflammation

• DCCT* indicated that patients with C-
peptide on MMTT ≥0.2 pmol/mL were less
likely to complicate of retinopathy and
hypoglycemia (Greenbaum et al 2012)

• Higher / sustained levels of C-peptide
correlate with reduced incidences of the
microvascular complications (Steffes et al
2013)

*Diabetes Control and Complications Trial

“We acknowledge the evidence from the DCCT and other studies that have
demonstrated clinical benefits in patients who achieve better glucose
control, in terms of delaying the chronic complications of diabetes”**

**FDA Guidance,

2008

AAT

Anti Inflammatory

blocks pro-Inflammatory
mediators incl. IL-1b, IL-6,
IL-8 and TNFa

Immunomodulatory

AAT promotes Tregs and
modifies dendritic cell
maturation towards a
tolerance-inducing profile

Tissue protective -

Protects from cell death,
blocks apoptosis

Regulatory T cell
differentiation

AAT promotes Tregs
differentiation

Increases insulin release

AAT increases cAMP levels
(required for insulin release).
cAMP also induces IL-10
release

Protease Inhibitor

Inhibits proteins that activate
inflammation: Elastase, trypsin
& PR3 and has tissue-protective
effects

Modifies dendritic cells:

AAT modifies dendritic cell
maturation towards a tolerance-
inducing profile

Protect islets from injury

AAT protects islet cells from

IL-1b/IFNg-induced injury and
reduces the levels of released
nitric oxide

Reference: Fleixo-Lima et al. Mechanistic Evidence in Support of Alpha1-Antitrypsin as a
Therapeutic Approach for Type 1 Diabetes. J Diabetes Sci Technol. 2014.

Investor Presentation | Sep. 2014

Clinical Development for Newly Diagnosed Type‐1
Diabetes: New Exciting Prospects

Phase I/II Open Label Study to evaluate the safety, tolerability and efficacy of AAT (Glassia®) on beta
cell preservation and glycemic control on newly diagnosed T1D pediatric patients.

• AUC% for C-peptide decreased 23% from baseline vs. ~40-50% expected decrease after 12-15M from diagnosis (1)

• Specific diabetes antibody levels decreased in all groups from baseline to study completion, a decrease that may indicate
an Immune modulatory effect.

• At end-of-study, 38% of patients decreased insulin dose

• All subjects completed the study. No Serious AEs occurred. AEs were mild and mostly infusion-related (fatigue, headache)

End-of-study slope analysis of C-peptide[max] and C-
peptide[AUC] revealed no significant changes from baseline

HbA1C data indicated that almost all patients reached
glycemic control

Investor Presentation | Sep. 2014

1. Greenbaum et al 2012

Currently ongoing
Phase II/III Clinical Trial

Study objective: To evaluate the Efficacy and Safety
of Human, Alpha-1 Antitrypsin (AAT) [Glassia®] in the
treatment of New Onset Type 1 Diabetes.

Design: Two doses, placebo controlled, randomized
with ~190 pediatric and young adult patients.

Expected Duration: Two years.

Endpoints: In accordance with FDA / EMA guidance
for clinical trials evaluating beta-cell preservation [c
peptide parameters, HbA1C, hypoglycemic events and
insulin daily dose].

Pivotal, Phase II/III, Double
-Blind, Randomized,
Placebo-Controlled,
Multicenter study.

Investor Presentation | Sep. 2014

• Donor’s immune cells (the graft) recognize the recipient (the host) as “Non-self“.
The transplanted immune cells attack the host's body cells.

• Deadly side effects:

Ø ~20% of transplanted patients die of GvHD complications

Ø ~70% mortality in patients with grade iii-iv GvHD

Ø ~60% of patients are non responsive to steroids

• Searching for an effective treatment

Ø Standard of care prophylaxis exhibits poor efficacy/severe AE’s (Glucocorticoids)

Ø No FDA approved specific drug for GvHD indication

• Estimated market size: ~ $0.5 billion

Graft versus Host Disease (GvHD): The Pro Major
Issue in Hematopoietic Stem Cell Transplantation

Investor Presentation | Sep. 2014

• Phase I/II study open label of 24 patients with steroid-resistant GVHD following allogeneic bone-
marrow stem cell transplant

• Dose: 4 dose groups - 15 day regimen. Doses given on days: 1,3,5,7, 9, 11, 13 and 15

• Primary End Points: % of patients at each dosing cohort who experience no toxicity and in whom
GVHD is stable or improved

• Secondary End Points - AAT levels, cytokine levels, infection rate, progression of GVHD, SAEs.

• In cooperation with Baxter, conducted at the Fred Hutchinson Cancer Research Center in Seattle,
Washington

• Interim Report by the end of 2014

Proof-of-Concept Study with AAT (IV) for Graft-Versus-
Host Disease (GVHD)

This proof-of-concept study may serve as a potential platform,
to expand the use of GLASSIA beyond GVHD, to other transplantations,
based on a similar mechanism of action

Investor Presentation | Sep. 2014

Integrated, Efficient, Scalable Platform Technology

Fully-Invested Manufacturing
Facility & Marketed Products

• FDA approved since 2010

• cGMP compliant

• Multiple countries' certifications
(US, Brazil, Israel, Mexico, Russia)

• State-of-the-art clean room
environment

• Located in Beit Kama, Israel

Proprietary, Innovative and
Patented Technology Platform

• Patent protected:
Chromatography-based
purification process

• Enables high purity extraction

• Ready-to-use, liquid and stable
specialty protein therapeutics
(AAT, Albumin, Transferrin and
many others)

• Enables production of almost any
human plasma-derived specific
immunoglobulins

Benefits

• Enables manufacturing of plasma-
derived protein therapeutics with
differentiated product profiles

• Efficient production process with
higher yield than manufacturing
methods employed by competitors

• High safety profile and proven
track record

• Infrastructure in place to meet
future pipeline product demand

• Expandable product platform to
additional territories and
indications

Investor Presentation | Sep. 2014

FINANCIALS

Investor Presentation | Sep. 2014

Existing Anchor
Products

§ Profitable unit

§ Sales in 15 countries

§ Predictable, stable
business

($0.5B)*

Existing Anchor Products

Glassia®
(AAT-IV) in US

Inhaled AAT for AATD in
Europe & US

New Geographies

Additional
Unencumbered Pipeline
Products

Glassia®
(AAT-IV)

in US&ROW

§ Estimated only ~5% of
cases treated in US

§ Annual therapy costs
~$80K - $100K per patient

§ Partnered with Baxter
solely for IV products in
the US (agreement also
covers Canada, Australia
and New Zealand)

§ Key geographies retained

(100K pts.,$0.75-1B)*

New Geographies

§ Potential to sell existing
and new products into
new geographies

§ Rabies Ig to US and
additional territories

§ Capital-efficient
strategy minimizes
outlay required by
Kamada

($0.5B)*

Additional
Unencumbered
Pipeline Products

§ D1-AAT (IV):
Type-1 diabetes in Phase
I/II (Unencumbered
outside of US, Canada,
Australia and New
Zealand)
(100K pts.,$3.5-5B)*

§ G1-AAT (IV)

GVHD phase I/II in
process
($0.5-1B)*

§ C1-AAT (IH):
Cystic fibrosis completed
Phase II (Unencumbered)
(100K pts.,$0.5-1B)*

§ B1-AAT (IH):
Bronchiectasis completed
Phase II (Unencumbered)
(600K pts.,$2B)*

Inhaled AAT for
AATD in
Europe & US

§ Estimated only ~2% of
cases treated in Europe

§ Estimated only ~5% of
cases treated in US

§ Orphan drug designation
in US and EU

§ Partnered with Chiesi for
Inhaled AAT for AATD in
Europe only

§ Distribution (no
technology out-licensed
in Europe)

§ Unencumbered in US

(200K pts.,$1-2B)*

The Kamada
Pillars

* Estimated market potential

Investor Presentation | Sep. 2014

• Pipeline products expected to accelerate revenue growth

• Better product mix expected to improve gross margin

• Strategic partnership model results in efficient operating expenses

• Stable, profit generating revenue stream from marketed products

• Low capital expenditure to support infrastructure meeting future demand

• Preferred tax treatment under Israeli law

Strong Financial Profile with Revenue Growth and
Expanding Profitability

Investor Presentation | Sep. 2014

$MM	FY2009	FY2010	FY2011	FY2012	FY2013
Proprietary Products	10	23	35	47	51
Growth		130%	54%	32%	9%
Distribution	4	11	24	26	20
Growth		187%	110%	8%	(23%)
Total Revenues	14	34	59	73	71
Growth		146%	73%	22%	(3%)
Gross Profit	(3)	6	17	23	26
R&D	(9)	(9)	(12)	(12)	(13)
S&M and G&A	(5)	(7)	(7)	(7)	(2)(10)
NET PROFIT (LOSS) Adjusted EBITDA (1)	(21) (12)	(14) (6)	(4) 1	0.3 9	0.4 9

Note

1. See Appendix for a reconciliation of Adjusted EBITDA to IFRS Net Profit (Loss)

2. Includes one time IPO related expenses of $1.4 M

Investor Presentation | Sep. 2014

Consistent Track Record of Execution

Initial Public Offering on the Tel Aviv Stock Exchange (KMDA)
Strategic agreement with PARI Pharma GmbH
US FDA approval for Glassia®
Strategic agreement with Baxter & First Glassia® sale in the US
Strategic agreement for Rabies in the US with Kedrion
Anti-Snake Venom launch
Strategic agreement with Chiesi
Newly diagnosed type-1 diabetes Phase II trial completed
Initiation of Phase II/III for type-1 diabetes
Initiation of Phase II for Inhaled AAT for AATD in the US
Completion of Phase II/III Inhaled AAT for AATD trial (EU)
Completion of Phase III Rabies Ig (US)
Increased sales, profitability and production capacity

August 2005

August 2014

Investor Presentation | Sep. 2014

Future Milestones and Value Creation

Phase III Rabies Ig trial (US) results	4Q14
EMA discussion on conditional approval	4Q14
MAA submission for Inhaled AAT for AATD	2015
BLA submission for the Rabies lg in the US	2015
Completion of Phase II for Inhaled AAT for AATD trial (US)	2015
Expansion to additional territories of Phase II/III for type-1 diabetes	2015
Initiation of Phase ll for intrevenous AAT for GVHD	2015
Strategic agreements	2015
Rabies product launch in the US (if approved)	2016
Inhaled AAT for AATD launch (EU) (if approved)	2016
Interim report for Phase II/III for type-1 diabetes trial	2016
AAT IV for newly diagnosed type-1 diabetes launch (if approved)	2017/18

Milestone Date

Investor Presentation | Sep. 2014

Kamada Investment Highlights

Rapidly Growing, Globally Positioned Biopharmaceutical Company

- Focused on Orphan Diseases and Plasma Derived Protein Therapeutics

Significant Opportunity in Novel Inhaled AAT for Alpha-1 Antitrypsin Deficiency
and in Intravenous AAT for Type-1 Diabetes

Valuable R&D Pipeline Focused on Various Orphan Indications

Integrated, Efficient and Scalable Best-in-class Patented Platform Technology and Know-How

Strong Financial Profile with Increasing Profitability

Validating Strategic Partnerships with Industry Leaders Baxter, Chiesi, Kedrion and Pari Pharma

Flagship Product Glassia® Approved for Alpha-1 Antitrypsin Deficiency Disorder

- Has a Unique and Differentiated Product Profile and Represents an Exciting Growth Opportunity

Investor Presentation | Sep. 2014

www.kamada.com

THANK YOU

Investor Presentation | Sep. 2014